Diabetes: Mellitus or lipidus?

Diabetologia

Volumn 46, Issue 3, 2003, Pages 433-440

  Shafrir, E ^a   Raz, I ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; PROTEIN KINASE C;

ATHEROSCLEROSIS; DIABETES MELLITUS; HYPERLIPIDEMIA; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW;

EID: 0037965858     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1052-5     Document Type: Review

References (100)

1. Dole VP (1956) A relation between nonesterified fatty acids in plasma and the metabolism of glucose. J Clin Invest 35:150-154
2. Gordon RS Jr, Cherkes A (1956) Unesterified fatty acid in human blood plasma. J Clin Invest 35:206-212
3. Reshef L, Shafrir E, Shapiro B (1958) In vitro release of unesterified fatty acids by adipose tissue. Metabolism 7:723-730
4. Ruderman NB, Toews CJ, Shafrir E (1969) Role of free fatty acids in glucose homeostasis. Arch Intern Med 123:299-313
5. Shafrir E, Gutman A (1965) Patterns of decrease of free fatty acids during glucose tolerance tests. Diabetes 14:77-83
6. Zierler KL, Rabinowitz D (1964) Effect of very small concentrations of insulin on forearm metabolism. Persistence of its action on potassium and free fatty acids without its effect on glucose. J Clin Invest 43:950-962
7. Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789
8. Randle PJ, Kerbey AL, Espinal J (1988) Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diabetes Metab Rev 4:623-638
9. Oliver MF (2002) Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. Am J Med 112:305-311
10. Jouven X, Charles M-A, Desnos M, Ducimetiere P (2001) Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 104:756-767
11. McGarry JD (1992) What if Minkowski had been ageusic? An altenative angle on diabetes. Lancet 258:766-770
12. Mering J von, Minkowski O (1890) Diabetes mellitus nach Pankreas-extirpation. Arch Exp Path Pharmakol. 26:371-387
13. Golay A, Felber JP, Jequier E, DeFronzo RA, Ferrannini E (1988) Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. Diabetes Metab Rev 4:727-747
14. Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176
15. Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10
16. Waldhäusl WK, Roden M (2000) The effects of free fatty acids on glucose transport and phosphorylation in human skeletal muscle. Curr Opin Endocrinol Diabetes 7:211-216
17. Roden M, Price TB, Perseghin G et al. (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97:2859-2856
18. Krebs M, Krssak M, Nowotny P et al. (2001) Free fatty acids inhibit the glucose-stimulated increase of intramuscular glucose-6-phosphate concentration in humans. J Clin Endocrinol Metab 86:2153-2160
19. 1H nuclear magnetic resonance spectroscopy in lean and obese adolescents. Diabetes 5:1022-1027
20. Pan DA, Lillioja S, Kriketos AD et al. (1997) Skeletal muscle triglyceride concentrations are inversely related to insulin action. Diabetes 46:983-988
21. Ebeling P, Essen-Gustavsson B, Tuominen JA, Koivisto VA (1998) Intramuscular triglyceride content is increased in IDDM. Diabetologia 41:111-115
22. Krssak M, Petersen KF, Dresner A, DiPietro L, et al. (1999) Intramyocellular lipid concentrations are correlated with insulin sensitivity in European and South Asian men. Diabetologia 42:932-935
23. 1H spectroscopy: validation in vivo. Am J Physiol 276: E977-E989
24. Dresner A, Laurent D, Marcucci M et al. (1999) Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259
25. Man ZW, Hirashima T, Mori S, Kawano K (2000) Decrease in triglyceride accumulation in tissues by restricted diet and improvement of diabetes in Otsuka Long-Evans Tokushima fatty rats, a non-insulin-dependent diabetes model. Metabolism 49:108-114
26. Greco AV, Mingrone G, Giancaterini A et al. (2002) Insulin resistance in morbid obesity. Reversal with intramyocellular fat depletion. Diabetes 51:144-151
27. Houmard JA, Tanner CJ, Chunli Y et al. (2002) Effect of weight loss on insulin sensitivity and intramuscular long-chain fatty acyl-CoAs in morbidly obese subjects. Diabetes 51:2959-2963
28. McGarry JD (2002) Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes (Banting Lecture 2001). Diabetes 51:7-18
29. Ellis BA, Poynten A, Lowy AJ et al. (2000) Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab 279:E554-E560
30. Itani SI, Ruderman NB, Schmieder F, Boden G (2002) Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 51:2005-2011
31. Dobbins RL, Szczepaniak LS, Bentley B et al. (2001) Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 50:123-130
32. Griffin ME, Marcucci MJ, Cline GW et al. (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase Cθ and alterations in the insulin signaling cascade. Diabetes 48:1270-1274
33. Shafrir E, Ziv E, Mosthaf L (1999) Nutritionally induced insulin resistance and receptor defect leading to β-cell failure in animal models. Annals NY Acad Sci 892:223-246
34. Shafrir E (2001) Albert Renold Memorial Lecture: molecular background of nutritionally induced insulin resistance leading to type 2 diabetes - from animal models to humans. Int J Exp Diabetes Res 2:299-319
35. Ikeda Y, Olsen GS, Ziv E et al. (2001) Cellular mechanism of nutritionally induced insulin resistance in Psammomys obesus. Overexpression of protein kinase Cε in skeletal muscle precedes the onset of hyperinsulinemia and hyperglycemia. Diabetes 50:584-592
36. Yu HY, Inoguchi T, Kakimoto M et al. (2001) Saturated non-esterified fatty acids stimulate de novo diacylglycerol synthesis and protein kinase C activity in cultured aortic smooth muscle cells. Diabetologia 44:614-620
37. Idris I, Gray S, Donnelly R (2001) Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 44:659-673
38. Seedorf K, Shearman M, Ullrich A (1995) Rapid and long-term effects of protein kinase C on receptor tyrosine kinase phosphorylation and degradation. J Biol Chem 270:18953-18960
39. deVente JE, Carey JO, Bryant WO, Pettit GJ, Ways DK (1996) Transcriptional regulation of insulin receptor substrate 1 by protein kinase C. J Biol Chem 271:32276-32280
40. Danielsen AG, Liu F, Hosomi Y, Shii K, Roth RA (1995) Activation of protein kinase Cα inhibits signaling by members of the insulin receptor family. J Biol Chem 270:21600-21605
41. Tanti JF, Gremeaux T, Van Obberghen E, Le Marchand-Brustel Y (1994) Serine/threonine phosphorylation of insulin receptor substrate 1 modulates receptor signaling. J Biol Chem 269:6051-6057
42. Chin JE, Liu F, Roth RA (1994) Activation of protein kinase Cα inhibits insulin-stimulated tyrosine phosphorylation of insulin receptor substrate-1. Mol Endocrinol 8:51-58
43. Muller HK, Kellerer M, Ermel B et al. (1991) Prevention by protein kinase C inhibitors of glucose-induced insulin-receptor tyrosine kinase resistance in rat fat cells. Diabetes 40:1440-1448
44. Kanety H, Moshe S, Shafrir E et al. (1994) Hyperinsulinemia induces a reversible impairment in insulin receptor function leading to diabetes in the sand rat model of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 91:1853-1857
45. Schmitz-Peiffer C, Browne CL, Oakes ND et al. (1997) Alterations in the expression and cellular localization of protein kinase C isozymes ε and θ are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 46:169-178
46. Kraegen EW, Carey DGP, Campbell LV (2000) Effects of lipids on blood glucose regulation and insulin action. In: Draznin B, Rizza R (eds) Clinical research in diabetes and obesity, Part I: Methods, assessment and metabolic regulation. Humana Press, Totova, NJ, pp 305-320
47. Vollenweider P, Menard B, Nicod P (2002) Insulin resistance, defective insulin receptor substrate 2-associated phosphatidylinositol-2' kinase activation, and impaired atypical protein kinase C (ζ/λ) activation in myotubes from obese patients with impaired glucose tolerance. Diabetes 51:1052-1059
48. Ruderman NB, Saha AK, Vavvas D, Eitters LA (1999) Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 276:E1-E18
49. Shafrir E, Ziv E, Saha AK, Ruderman NB (2002) Regulation of muscle malonyl-CoA levels in the nutritionally insulin-resistant desert gerbil, Psammomys obesus. Diabetes Metab Res Rev 18:217-223
50. Saha AK, Schwarsin AJ, Roduit R et al. (2000) Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside. J Biol Chem 275:24279-24283
51. Astrup A, Buemann B, Christensen NJ, Toubro S (1994) Failure to increase lipid oxidation in response to increasing dietary fat content in formerly obese women. Am J Physiol 266:E592-E599
52. Kelley DE, Goodpaster B, Wing RR, Simoneau JA (1999) Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity and weight loss. Am J Physiol 277:E1130-E1141
53. Blaak EE, Wagenmaker AJM (2002) The fate of [U-13C] palmitate extracted by skeletal muscle in subjects with type 2 diabetes and control subjects. Diabetes 51:784-789
54. Park H, Kaushik VK, Constant S et al. (2002) Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem 277:32571-32577
55. Hotamisligil GS, Murray D, Choy LN, Spiegelman BM (1994) Tumor necrosis fact α inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 91:4854-4858
56. Hotamisligil GS, Peraldi P, Budavari A et al. (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665-668
57. Paz H, Hemi R, LeRoith D et al. (1998) Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272:29911-29918
58. Schmitz-Peiffer C, Craig DL, Biden TJ (1999) Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 274:24202-24210
59. Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier J-C (2002) TNF-α is a predictor of insulin resistance in human pregnancy. Diabetes 51:2207-2213
60. Greenberg AS, McDaniel ML (2002) Identifying the links between obesity, insulin resistance and β-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 32:24-34
61. Mohamed-Ali V, Goorick S, Rawesh A et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor- α in vivo. J Clin Endocrinol Metabl 82:4196-4200
62. Steppan CM, Bailey ST, Bhat S et al. (2001) The hormone resistin links obesity to diabetes. Nature 409:307-312
63. Weyer C, Funahashi T, Tanaka S et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935
64. Steinberg D, Parthasarathy S, Carew TE et al. (1989) Beyond cholesterol: modifications of LDL which increase its atherogenicity. N Engl J Med 320:915-923
65. Brown MS, Goldstein JL (1983) Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52:223-261
66. Porter NA, Caldwell SE, Mills KA (1995) Mechanisms of free radical oxidation of unsaturated lipids. Lipids 30:277-290
67. Mietus-Snyder M, Friera A, Glass CK, Pitas RE (1977) Regulation of scavenger receptor expression in smooth muscle cells by protein kinase C. A role for oxidative stress. Arterioscler Thromb Vasc Biol 17:v969-978
68. Owens D, Tomkin GH (2003) Diabetes dyslipidaemia: novel treatment and prognosis in type 1 and type 2 diabetes. In: Raz I, Skyler J, Shafrir E (eds) Diabetes: from research to diagnosis and treatment. Martin Dunitz, London, pp 93-120
69. Laakso M, Lehto S, Penttila I, Pyorala K (1993) Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 88:1421-1430
70. Malmstrom R, Packard CJ, Caslake MJ et al. (1997) Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40:454-462
71. Goldberg IJ (1996) Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 37:693-707
72. De Man FH, Cabezas MC, Van Barlingen HH et al. (1996) Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 26:89-108
73. Taskinen MR (1987) Lipoprotein lipase in diabetes. Diabetes Metab Rev 3:551-570
74. Bar-On H, Levy E, Oschry Y, Ziv E, Shafrir E (1984) Removal defect of very-low-density lipoproteins from diabetic rats. Biochim Biophys Acta 793:115-118
75. Gaw A, Packard CJ, Lindsay GM et al. (1995) Overproduction of small, very low density lipoproteins (sf 20-60) on moderate hypercholesterolaemia: relationship between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res 36:158-171
76. Taskinen MR (2001) Pathogenesis of dyslipidemia in Type 2 diabetes. Exp Clin Endocrinol Diabetes 109 [Suppl 2]:173-181
77. Tkac I, Kimball BP, Lewis G et al. (1997) The severity of coronary atherosclerosis in Type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler Thromb Vasc Biol 17:3633-3638
78. Riemens S, Tol A van, Sluiter W et al. (1998) Elevated plasma cholesteryl ester transfer in NIDDM: Relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140:71-79
79. Lahdenpera S, Syvanne M, Kahri J, Taskinen M-R (1996) Regulation of low density lipoprotein particle size and distribution in NIDDM and coronary artery disease: importance of serum triglycerides. Diabetologia 39:453-461
80. Taggart C, Gibney K, Owens D et al. (1997) The role of dietary cholesterol in the regulation of postprandial apolipoprotein B48 levels in diabetes. Diabetes Med 14:1051-1058
81. Battula SB, Fitzsimons O, Moreno S et al. (2000) Postprandial apolipoprotein B48 and B100-containing lipoproteins in Type 2 diabetes: Do statins have a specific effect on triglyceride metabolism? Metabolism 49:1-7
82. Packard CJ, Demant T, Stewart JP et al. (2000) Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 41:305-318
83. Gianturco SH, Ramprasad MP, Song R et al. (1998) Apolipoprotein B48 or its apolipoprotein B100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor. Arterioscler Thromb Vasc Biol 18:968-976
84. Brown ML, Ramprasad PM, Umeda PK et al. (2000) A macrophage receptor for apo B48: cloning, expression and atherosclerosis. Proc Natl Acad Sci USA 97:7488-7493
85. Jacobs JRC, Evcimen ND, King GL (2003) New treatments for prevention of insulin resistance and diabetes complications: PKC involvement. In: Raz I, Skyler JS, Shafrir E (eds) Diabetes: from research to diagnosis and treatment. Martin Dunitz, London, pp 455-478
86. Crespin SR, Greenough WB, Steinberg D (1973) Stimulation of insulin secretion by long-chain free fatty acids. A direct pancreatic effect. J Clin Invest 52:1979-1984
87. Pick A, Clark J, Kubstrup C, et al. (1998) Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes 47:358-364
88. Shafrir E, Ben-Sasson R, Ziv E, Bar-On H (1999) Insulin resistance, β-cell survival, and apoptosis in type 2 diabetes: animal models and human implications. Diabetes Rev 7:114-123
89. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH (1994) β-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats fed a high fat diet. Proc Natl Acad Sci USA 91:10878-10882
90. Unger RH (1995) Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: Genetic and clinical implications. Diabetes 44:863-870
91. Lupi R, Dotta F, Marselli L, et al. (2002) Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets. Diabetes 51:1437-1442
92. Racette SB, Davis AO, McGill JB, Klein S (2002) Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus. Metabolism 51:169-174
93. Ciaraldi TP, Kong APS, Chu NV, Kim DD (2002) Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 51:30-36
94. McTernan PG, Harte AL, Anderson LA, et al. (2002) Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes 51:1493-1498
95. Fulgencio J-P, Kohl C, Girard J, Pegorier J-P (1996) Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45:1556-1562
96. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI (2000) mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 275:8456-8460
97. Gavrilova O, Marcus-Samuels B, Graham D et al. (2000) Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105:271-278
98. Gabriely I, Ma XH, Yang X et al. (2002) Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 51:2951-2958
99. Oakes ND, Camilleri S, Furler SM et al. (1997) The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availabiliaty in the rat. Metabolism 46:935-942
100. Mayerson AB, Hundal RS, Dufour S et al. (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802